Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer. 2018 Feb;26(2):539-48. doi: 10.1007/s00520-017-3863-9
Hauber AB, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer. 2018 Jan;26(1):251-60. doi: 10.1007/s00520-017-3841-2
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3
Xu J, Evans J, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience. 2013;7:351. doi: 10.3332/ecancer.2013.351.
De Bellis MD, Van Voorhees E, Hooper SR, Gibler N, Nelson LM, Hege SG, Payne ME, MacFall J. Diffusion tensor measures of the corpus callosum in adolescents with adolescent onset alcohol use disorders. Alcohol Clin Exp Res. 2008 Mar;32(3):395-404.